Hyloris Pharmaceuticals (HYL)

Last close As at 16/07/2025

EUR6.40

0.18 (2.89%)

Market capitalisation

EUR180m

Hyloris Pharmaceuticals is a Belgium-based specialty biopharma firm focused on reformulating and repurposing approved drugs. Its commercial-stage products includes Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic for the treatment of post-operative pain.

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Stijn Van Rompay

    CO-CEO

  • Thomas Jacobsen

    CO-CEO

  • Christophe Maréchal

    CFO

Thematics

thematic

Healthcare

Healthcare-focused trusts: A sector on the mend

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free